Michael Mulberry, Chief Executive Officer of the Company, commented, “ We are very excited to announce the completion of our KorrAI Technology Program. As we move forward, we anticipate that the ...
--Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne compared with placebo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback